Matinas BioPharma Holdings (MTNB) Return on Capital Employed (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Return on Capital Employed of 157.42% for Q1 2026, up 4723.0% year-over-year from 3.26% in Q1 2025, and down 58.06% quarter-over-quarter from 99.59% in Q4 2025.
Matinas BioPharma Holdings (MTNB) Return on Capital Employed (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Return on Capital Employed for 13 consecutive years, with 157.42% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4723.0% year-over-year to 157.42%; the TTM figure through Mar 2026 stood at 157.42% (up 4723.0% YoY), while the FY2025 annual figure was 82.25%, up 6949.0% from the prior year.
- Return on Capital Employed retreated to 157.42% in Q1 2026 per MTNB's latest filing, from 99.59% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 47.65% in Q1 2022 and bottomed at 204.65% in Q1 2025.
- Historically, Return on Capital Employed has averaged 107.44% across 5 years, with a median of 99.59% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 7678 bps in 2025 and fell as far as 8636 bps in 2025.
- Matinas BioPharma Holdings' Return on Capital Employed stood at 58.69% in 2022, then slumped by 63 bps to 95.73% in 2023, then sank by 84 bps to 176.37% in 2024, then surged by 44 bps to 99.59% in 2025, then tumbled by 58 bps to 157.42% in 2026.
- Business Quant data shows MTNB's Return on Capital Employed at 157.42% in Q1 2026, 99.59% in Q4 2025, and 152.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Matinas BioPharma Holdings | 1.18 Mn | 369,661.04 | - | -202.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -202.49% |
| Mar 31, 2026 | -157.42% |
| Dec 31, 2025 | -99.59% |
| Sep 30, 2025 | -152.56% |
| Jun 30, 2025 | -167.24% |
| Mar 31, 2025 | -204.65% |
| Dec 31, 2024 | -176.37% |
| Sep 30, 2024 | -108.17% |
| Jun 30, 2024 | -121.26% |
| Mar 31, 2024 | -118.29% |
| Dec 31, 2023 | -95.73% |
| Sep 30, 2023 | -81.45% |
| Jun 30, 2023 | -67.61% |
| Mar 31, 2023 | -56.64% |
| Dec 31, 2022 | -58.69% |
| Sep 30, 2022 | -57.28% |
| Jun 30, 2022 | -55.91% |
| Mar 31, 2022 | -47.65% |
| Dec 31, 2021 | -41.36% |
| Sep 30, 2021 | -38.07% |